Rheumatology

 Findings from the ARTIS study group suggest that biologic disease-modifying antirheumatic drugs and tumor necrosis factor inhibitors are not associated with an increased overall cancer risk compared with conventional synthetic DMARDs.

The addition of high-dose glucocorticoids to first-line adalimumab and methotrexate in the treatment of rheumatoid arthritis fails to further improve efficacy, results of a phase IV study show.

Meta-analysis findings have confirmed an excess risk for cardiovascular events in patients with rheumatoid arthritis, but also show that this excess risk has declined since the year 2000.

Spondyloarthritis-related comorbidities are associated with ankylosing spondylitis, undifferentiated spondyloarthritis, and psoriatic arthritis subtypes of the disease, show study findings.

Fibromyalgia could contribute to patients with rheumatoid arthritis not reaching remission, concludes research presented at EULAR 2017.

Researchers have identified baseline predictors of clinical remission in patients with non-radiographic axial spondyloarthritis taking tumor necrosis factor inhibitors.

The beneficial effects of abatacept treatment for patients with psoriatic arthritis are maintained for up to 1 year, suggest follow-up results of the ASTRAEA trial presented at EULAR 2017.

Study results suggest that  high-sensitivity cardiac troponin T could be a predictive biomarker of cardiovascular risk among patients with systemic lupus erythematosus.

Phase III trial results presented at EULAR 2017 and published in The Lancet suggest that  ixekizumab is a promising treatment option for patients with psoriatic arthritis.

Levels of three proteins in the urine are significantly elevated among children with lupus nephritis compared with controls, results of an interim analysis of a multicenter study suggest.

Psoriatic arthritis patients with comorbidities have higher disease activity and worse treatment response than those without comorbidities, study results presented EULAR 2017 suggest.

Two studies presented at EULAR 2017 have highlighted new tools that could help diagnose systemic sclerosis in the early stages, supporting the EULAR campaign: “Don’t delay, Connect Today!”

Results of a systematic review and meta-analysis suggest that very early therapeutic intervention could reduce the risk for disease onset among patients with pre-rheumatoid arthritis.

Study findings highlight the need to address negative feelings related to treatment decisions among patients with rheumatoid arthritis.

Phase III trial results suggest that ABP 501 – the first US FDA-approved adalimumab biosimilar – has a similar efficacy, safety, and immunogenicity profile to its reference drug for the treatment of patients with moderate-to-severe rheumatoid arthritis.

Treatment with teriparatide, a recombinant form of parathyroid hormone, does not reduce joint erosion among patients with rheumatoid arthritis undergoing treatment with tumor necrosis factor inhibitors, researchers report.

Results of a randomized trial suggest that pharmaceutical-grade chondroitin sulfate is as effective as the non-steroidal anti-inflammatory drug celecoxib for reducing pain and improving function among patients with symptomatic knee osteoarthritis.

Results of a randomized trial suggest that rheumatoid arthritis patients with low disease activity who receive telephone-based follow-up achieve similar disease control to those receiving conventional outpatient follow-up.

An analysis of two US cohorts suggests that higher dietary fiber intake is associated with lower risk for symptomatic osteoarthritis.

Click through to read more on this US FDA decision